Global Arginase Deficiency Market, By Diagnosis (Genetic Testing, New-born Screening Others), Treatment (Nitrogen-Binding Adjunctive, Nitrogen Scavenger Drugs, Anti-Seizure Drugs, Intravenous (IV) Fluids, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others) – Industry Trends and Forecast to 2030.
Arginase Deficiency Market Analysis and Size
Arginase deficiency is a rare type of deficiency and it is projected that about 1 in 300,000 to 1,000,000 individuals. Though, these disorders often go under-diagnosed because urea cycle disorders such as NAGS deficiency often go unrecognized, thus making it difficult to decide the actual frequency of urea cycle disorders in the general population. The technological advancement in treatment and diagnosis and increasing genetic inherited disorders also boost up the market growth. But severe effect related to the treatment, lack of etiology and low incidence rate may hamper the arginase deficiency market.
Data Bridge Market Research analyses a growth rate in the arginase deficiency market in the forecast period 2023-2030. The expected CAGR arginase deficiency market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 100 million in 2022, and it would grow upto USD 136.8 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Arginase Deficiency Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Diagnosis (Genetic Testing, New-born Screening Others), Treatment (Nitrogen-Binding Adjunctive, Nitrogen Scavenger Drugs, Anti-Seizure Drugs, Intravenous (IV) Fluids, Others), Drug Type (Branded, Generic), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, online Pharmacies and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Horizon Therapeutics plc (Dublin), Bausch Health Companies Inc. (Canada), Sigmapharm Laboratories, LLC (U.S.), Par Pharmaceutical. (U.S.), Aeglea BioTherapeutics (Austin)
|
|
Market Opportunities
|
|
Market Definition
Arginase deficiency is a type of inherited metabolic disorder that is characterized by the partial and complete lack of arginase enzyme in the red blood cells and liver. The lack of arginase enzyme causes excessive accumulation of nitrogen in the form of arginine and ammonia in the cerebrospinal fluid and blood. If the deficiency is not treated on time properly, it may lead to spasticity, short stature, seizures, and intellectual disability may occurs. The accumulation of ammonia in the blood causes the symptoms of NAGS deficiency. In the most extreme cases, the symptoms of this deficiency occur within 24-72 hours after birth.
Arginase Deficiency Market Dynamics
Drivers
- Growing Adoption of Injectable Route of Administration
Injection arginase deficiency drugs are used in cases where oral medications are either unavailable or unsuitable for specific patients such as infants, children, and those suffering from severe kidney disease, and other conditions that prevent normal pill consumption. In addition to this, it also aids in improving patient adherence to their prescribed medication, further improving their health condition.
Opportunities
- Increasing Demand For Hospitals
Drug stores and hospitals consider to be the major application segments of arginase deficiency drugs. In 2015, the hospital segment dominated the global market with a more than 80% revenue share. The segment is estimated to witness major growth due to increasing healthcare expenditure and a growing number of patients suffering from life-threatening diseases such as cancer, who require intravenous (IV) nutrition for treatment.
- Varied Options For Diagnostic Tests
A diagnosis of NAGS deficiency can be done through a detailed patient or family history, identification of specialized findings, and a variety of particular tests. Blood tests may show excessive amounts of ammonia in the blood, which is the primary finding of urea cycles disorders. Though, increased levels of ammonia in the blood may describe other disorders such as the congenital lactic acidosis, organic acidemias, and fatty acid oxidation disorders. Urea cycles disorders can be distinguished from these disorders through the examination of urine for increased levels of or abnormal organic acids.
Restraints/Challenges
- Lack of Awareness
For many decades, this deficiency disease is not much known in several parts of the world. The appropriate treatment for the disease and its associated applications are unaware to the people. Thus, it hampers the market growth.
- High Cost of Treatment Process
The enormous expenditure required for its treatment processes obstructs the market growth. Numerous market players make huge investments in manufacturing new and advanced treatment procedures to faster the recovery process and in return the cost is increased.
This arginase deficiency market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the arginase deficiency market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Arginase Deficiency Market Scope
The arginase deficiency market is segmented on the basis of diagnosis, treatment, drug type, end-user distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Diagnosis
- Genetic Testing
- New-born Screening
- Others
Treatment
- Nitrogen-Binding Adjunctive
- Nitrogen Scavenger Drugs
- Benzoate
- Phenylacetate (PA)
- phenylbutyrate (PB)
- Anti-Seizure Drugs
- Carbamazepine
- Oxcarbazepine
- Trileptal
- Oxtellar XR
- Lamotrigine
- Lamictal
- Phenytoin
- Dilantin
- Intravenous (IV) Fluids
- Others
Drug Type
- Branded
- Generic
End-Users
- Hospitals
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
- Others
Arginase Deficiency Market Regional Analysis/Insights
The arginase deficiency market is analyzed and market size insights and trends are provided by diagnosis, treatment, drug type, end-user distribution channel as referenced above.
The major countries covered in the arginase deficiency market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America is dominating the market due to the presence of high healthcare expenditure and research and development.
Asia-Pacific is considered to grow over the coming years due to increased advancement in the technology as well as growing healthcare expenditure.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Arginase Deficiency Market Share Analysis
The arginase deficiency market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to arginase deficiency market
Key players operating in the arginase deficiency market include:
- Horizon Therapeutics plc (Dublin)
- Bausch Health Companies Inc. (Canada)
- Sigmapharm Laboratories, LLC (U.S.)
- Par Pharmaceutical. (U.S.)
- Aeglea BioTherapeutics (Austin)
SKU-